Corporation
Hoffmann-La Roche Limited
- Meetings this Parliament
- 26
- With MPs
- 10
- Since Nov 2021
- 168
- Active registrations
- 1
Most recent reported meeting: Sep 29, 2026.
Lobbying by Hoffmann-La Roche Limited: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Sep 30, 2026
Filed by Stefanos Tsamousis, PRESIDENT AND CHIEF EXECUTIVE OFFICER
Lobbyists
- Bill Zindle · Executive Director, Strategy and Marketing
- Cassondra McCrory · Healthcare System Partner Federal
- Donna Janzen · Director Regulatory Strategy & Policy
- Michele D'Elia · Executive Director, Medical & Scientific Affairs
- Roger Tam · Vice President, Legal
- Shikha Virdi · Chapter Lead, Policy & Healthcare Ecosystems
- Stefanos Tsamousis · PRESIDENT AND CHIEF EXECUTIVE OFFICER
Institutions they may lobby: Canadian Institutes of Health Research (CIHR), Environment and Climate Change Canada (ECCC), Federal Economic Development Agency for Southern Ontario (FedDev), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), National Research Council (NRC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (15)Hide details
- The Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of importation legislation in the United States.
- Pharmaceutical intellectual property protection as it relates to international trade agreements
- Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products.
- Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's biomanufacturing and life sciences sector strategy
- Food and Drugs Act updates, as it relate to the reform of clinical trial applications, and drug/device submission review and approval process. Scope includes new drug submissions/indications and post market submissions, reliance & recognition pathways, service standards, fees, biosimilars, clinical trial modernization.
- Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
- Standing Committee on Finance (FINA) as it relates to pre-budget consultations.
- The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability, and as it relates to Canada’s Biomanufacturing and Life Sciences Strategy.
- Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies.
- Income Tax Act as it relates to biopharmaceutical industry.
- Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry, and related updates and to Federal budgetary policy.
- House of Commons Standing Committee of Industry and Technology (INDU) as it relates to Artificial Intelligence and/or any other pertinent legislative proposal before the committee
- Patented Medicines Prices Review Board (PMPRB), as it relates to reporting requirements, pricing guidelines, and dispute resolution
- Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry
- Clinical Trials environment in Canada: operational issues, investment, enrollment
Registration 966507-64-73. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Brigitte Nolet (114), Ronnie Miller (39), Stefanos Tsamousis (8), Dan Edgcumbe (7).
-
Reported by Ronnie Miller · In-house (corporation)
- Sébastien Aubertin-Giguère · Assistant Deputy Minister, Health Canada (HC)
Health
-
Reported by Ronnie Miller · In-house (corporation)
- Sébastien Aubertin-Giguère · Assistant Deputy Minister, Health Canada (HC)
Health
-
Reported by Ronnie Miller · In-house (corporation)
- Arianne Reza · Associate Deputy Minister, Public Services and Procurement Canada (PSPC)
- Michael Mills · Assistant Deputy Minister, Public Services and Procurement Canada (PSPC)
Health
-
Reported by Ronnie Miller · In-house (corporation)
- Justin Trudeau · Prime Minister of Canada, Prime Minister's Office (PMO)
Health
-
Reported by Ronnie Miller · In-house (corporation)
- Arianne Reza · Associate Deputy Minister, Public Services and Procurement Canada (PSPC)
- Michael Mills · Assistant Deputy Minister, Public Services and Procurement Canada (PSPC)
Health
-
Reported by Ronnie Miller · In-house (corporation)
- Arianne Reza · Associate Deputy Minister, Public Services and Procurement Canada (PSPC)
- Michael Mills · Assistant Deputy Minister, Public Services and Procurement Canada (PSPC)
Health
-
Reported by Ronnie Miller · In-house (corporation)
- Sébastien Aubertin-Giguère · Assistant Deputy Minister, Health Canada (HC)
Health
-
Reported by Ronnie Miller · In-house (corporation)
- Michael Mills · Assistant Deputy Minister, Public Services and Procurement Canada (PSPC)
Health
-
Reported by Ronnie Miller · In-house (corporation)
- Sébastien Aubertin-Giguère · Assistant Deputy Minister, Covid-19 Testing, Contact Tracing and Data Management Strategies, Health Canada (HC)
Health
-
Reported by Ronnie Miller · In-house (corporation)
- Sébastien Aubertin-Giguère · Assistant Deputy Minister, Covid-19 Testing, Contact Tracing and Data Management Strategies, Health Canada (HC)
- Michael Mills · Assistant Deputy Minister, Public Services and Procurement Canada (PSPC)
Health
-
Reported by Ronnie Miller · In-house (corporation)
- Sébastien Aubertin-Giguère · Assistant Deputy Minister, Covid-19 Testing, Contact Tracing and Data Management Strategies, Health Canada (HC)
- Michael Mills · Assistant Deputy Minister, Public Services and Procurement Canada (PSPC)
Health
-
Reported by Ronnie Miller · In-house (corporation)
- Michael Mills · Assistant Deputy Minister, Public Services and Procurement Canada (PSPC)
Health
-
Reported by Ronnie Miller · In-house (corporation)
- Sébastien Aubertin-Giguère · Assistant Deputy Minister, Covid-19 Testing, Contact Tracing and Data Management Strategies, Health Canada (HC)
Health
-
Reported by Ronnie Miller · In-house (corporation)
- Sébastien Aubertin-Giguère · Assistant Deputy Minister, Covid-19 Testing, Contact Tracing and Data Management Strategies, Health Canada (HC)
Health
-
Reported by Ronnie Miller · In-house (corporation)
- Jean-Sébastien Bock · Director of Policy, Health Canada (HC)
Health
-
Reported by Ronnie Miller · In-house (corporation)
- Dylan Marando · Senior Policy Advisor, Employment and Social Development Canada (ESDC)
Industry
-
Reported by Ronnie Miller · In-house (corporation)
- Sébastien Aubertin-Giguère · Assistant Deputy Minister, Covid-19 Testing, Contact Tracing and Data Management Strategies, Health Canada (HC)
Health
-
Reported by Ronnie Miller · In-house (corporation)
- Sébastien Aubertin-Giguère · Assistant Deputy Minister, Covid-19 Testing, Contact Tracing and Data Management Strategies, Health Canada (HC)
Health
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.